Insider Buying: Bioamber Director Buys 2,980 Shares of Stock (BIOA)
Bioamber (NASDAQ:BIOA) Director Kurt W. Briner acquired 2,980 shares of the stock in a transaction dated Monday, August 11th. The stock was purchased at an average price of $11.45 per share, with a total value of $34,121.00. Following the transaction, the director now directly owns 36,180 shares in the company, valued at approximately $414,261. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Bioamber (NASDAQ:BIOA) traded up 1.12% during mid-day trading on Tuesday, hitting $11.69. 32,611 shares of the company’s stock traded hands. Bioamber has a 52-week low of $3.96 and a 52-week high of $15.29. The stock has a 50-day moving average of $11.56 and a 200-day moving average of $11.49. The company’s market cap is $217.0 million.
Bioamber (NASDAQ:BIOA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.44) by $0.04. Analysts expect that Bioamber will post $-1.78 EPS for the current fiscal year.
A number of analysts have recently weighed in on BIOA shares. Analysts at Societe Generale raised their price target on shares of Bioamber to $16.00 in a research note on Friday, July 18th. Separately, analysts at Barclays cut their price target on shares of Bioamber from $22.00 to $20.00 in a research note on Thursday, July 17th. Finally, analysts at Barclays raised their price target on shares of Bioamber from $13.00 to $22.00 in a research note on Thursday, July 10th. They now have an “overweight” rating on the stock.
BioAmber Inc (NASDAQ:BIOA) is a chemical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.